Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- National Advertising Division Finds Hims & Hers Has Support for Combination Efficacy Message; Recommends Modification or Discontinuance of Other ClaimsNew York, NY – August 24, 2026 – In a challenge brought by Kenvue Inc., BBB National Programs’ National Advertising Division determined that Hims & Hers Health, Inc. provided a reasonable basis for its comparative efficacy claim. However, the National […]
- Number of Shares and Voting Rights of ADOCIA as of July 31st, 2026LYON, France, August 24, 2026--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French "Code de Commerce" and article 223-16 of the General Regulation of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF"), ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon (Euronext Paris: FR0011184241 – ADOC – the "Company") a clinical-stage biopharmaceutical company focused on the research and development of i
- GUTS INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Fractyl Health, Inc. Investors – Holzer & Holzer, LLC Encourages Investors With Losses to Contact the FirmA shareholder class action lawsuit has been filed against Fractyl Health, Inc. (“Fractyl”) (NASDAQ: GUTS). The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts, including allegations that: (i) Revita was less effective than Defendants had led investors to believe, and/or operational issues at one or more of the REMAIN-1 Midpoint Cohort’s clinical sites compromised the integrity of its efficacy results; and (ii) accordingly, Revita’s clinical, regulatory, and commercial prospects were overstated, as was the REMAIN-1 Midpoint Cohort’s ability to assess Revita’s efficacy.
- AI Disrupts the Functional Foods and Beverages Sector as Industry Giants Deploy Personalization, Formulation, and Sustainability Technologies at Scale“AI is helping functional nutrition become more personalized, science-driven and responsive to changing consumer health needs.”
- Kessler Topaz Meltzer & Check, LLPHIMS INVESTIGATION NOTICE: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the FirmKessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who...
- Zealand Pharma – Notification of holding of treasury sharesCompany announcement – No. 42 / 2026
- BRC TherapeuticsBRC Therapeutics Appoints Biopharma Veteran Chandra Ramanathan as Executive Vice President of Commercialization and StrategySeasoned Executive Brings Track Record of Drug Launches, External Innovation, and Portfolio Growth at Bristol Myers Squibb, Wyeth, Bayer, and Danaher to BRC's Next Phase of Growth — BRC Therapeutics (BRC), a clinical-stage pharmaceutical...
- Endoscopes Market Size to Reach USD 41.09 Billion by 2035 as Disposable and AI-Assisted Systems Gain Ground – SNS InsiderU.S. Endoscopes Market projected at USD 12.09 billion by 2035 on rising hospital procedures; Europe reaches USD 8.33 billion, supported by established health coverage and device manufacturing.
- Zealand Pharma - Transactions related to share buy-back program (week 34, 2026)Company announcement No. 41 / 2026
- Imricor Medical Systems, Inc.Imricor Supports HRS Call for Enhanced Radiation Protection and Urges a Future Beyond Radiation ExposureMINNEAPOLIS, August 24, 2026--Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR), the pioneer in the interventional magnetic resonance (iMR) field, welcomed the Heart Rhythm Society’s call for the urgent and immediate adoption of enhanced radiation-protection measures for clinicians and staff working in fluoroscopy-based procedure environments.1
- Kaplan Fox & Kilsheimer LLPKaplan Fox Reminds Hims & Hers Health, Inc. (HIMS) Investors of an Investigation into Potential Securities Law ViolationsKaplan Fox & Kilsheimer LLP is investigating potential securities violations against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS).CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATIONIf you are a Hims & Hers investor and have suffered losses, or if you have information that could assist in the Hims & Hers investigation, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing...
- BrainStorm Cell Therapeutics Inc.BrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel SessionsExecutive Chairman and Former FDA Associate Commissioner Peter J. Pitts to deliver keynote presentations on establishing an FDA Abraham Accords Office and restructuring NIH research grant models. Pitts to moderate expert sessions on Translational Pharmaceutical Innovation and the Emerging...